Hepatitis C Virus (HCV) infection is a prevalent global community concern, recently developed Direct Acting Antiviral Drugs (DAA’s) offer significant opportunity for not only cure of the estimated fifty million individuals globally with HCV, but elimination of HCV as a global public health threat, respecting and attaining World Health Organization (WHO) goals of elimination as a public health threat by 2030. A challenge in reducing the burden of care on health systems with progression of asymptomatic HCV infection to chronic conditions, is standardized screening and testing, to scale. Especially in People Who Inject Drugs (PWID) the prevalent priority population most at risk of HCV infection. And due to the illegal nature of behaviors, a highly stigmatized and vulnerable population extremely hard to reach in terms of providing diagnosis and treatment of HCV. A key resource to facilitate HCV treatment of PWID involves the peer workforce of those with lived and living experience of injecting who, in this definition, have the advantage of being understood and accepted as frontline workers by PWID, and are a key resource to population wide HCV treatment enabling decentralized community-based practice, care of community by community. Towards increased efficacy of HCV elimination, our research has evidenced that by leveraging Emergent Disruptive Technologies (EDT) to formalize qualification and provide a systemized supported framework for facilitating HCV care navigation by peers; we can contribute to financial, health and community benefits with improved destigmatized health care access and lessened burdens on existing health systems!